BSEInsider Trading / SAST1d ago · 24 Sept 2026, 06:12 pm

Pursuant to SEBI (PIT) Regulations, 2015 as amended and as per Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Thursday, 01st October, 2026 till 48 hours after the date of Board Meeting wherein, inter-alia, the approval of Un-Audited Standalone and Consolidated Financial ....

Eiko Lifesciences Ltd · 540204

✦ AI SummaryResults

Eiko Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the Board Meeting where the Un-Audited Standalone and Consolidated Financial Results for the quarter ended September 30, 2026, will be considered.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Eiko Lifesciences Ltd - 540204 - Closure of Trading Window

Attachments (1)

📄

b43c2669-ddfe-483c-bd36-5114266e6bde.pdf

pdf

Download →
View document text
Date: 24th September, 2026 Corporate Services Department, BSE Limited Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai – 400 001. Scrip Code: 540204 Subject: Intimation Regarding the Closure of Trading Window Dear Sir/ Ma'am, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended and as per Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders (“Code”), the trading window for dealing in the securities of the Company shall remain closed for designated persons and their immediate relatives from Thursday, 01st October, 2026 till 48 hours after the date of Board Meeting wherein, inter-alia, the approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th September, 2026 would be considered by the Board. The date of the Board Meeting for consideration of the Un-Audited Financial Results of the Company for the quarter ended 30th September, 2026 will be intimated separately in due course. Accordingly, all Designated Persons and their immediate relatives are advised not to trade in the securities of the company during the aforesaid trading window closure period. This is for your information and records. Yours Faithfully, For Eiko Lifesciences Limited Chintan Doshi Company Secretary and Compliance Officer Membership No: A36190 Eiko LifeSciences Limited CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Phone No.: +919082668855; Email id: investor.relations@eikolifesciences.com: website:www.eikolifesciences.com